Purpose To characterize the efficacy and safety of palifermin in reducing the incidence of
oral mucositis (OM) and diarrhea when administered to patients with metastatic colorectal …

Abstract Background Data and Objective: Patients who have received high doses of
chemotherapy, either alone or in combination with total body irradiation often cite oral …

PURPOSE: From the demonstration of a circadian rhythm in the human oral mucosa cell
cycle, with most cells in the G1 phase in the morning and M phase at night, we hypothesized …

Background Glutamine is the primary fuel for the gastrointestinal epithelium and maintains
the mucosal structure. Oncologists frequently encounter oral mucositis, which can cause …

Abstract Introduction Irinotecan (CPT-11) is an inhibitor of DNA topoisomerase I and is
clinically effective against several cancers. A major toxic effect of CPT-11 is delayed …

Oral cancer patients receiving chemotherapy/radiotherapy experience oral mucositis (OM), a
condition believed to significantly impact the quality of life and treatment outcome. Artificial …

The current treatment for cervico-facial cancer involves radio and/or chemotherapy.
Unfortunately, cancer therapies can lead to local and systemic complications such as …

Background Oral mucositis occurs in patients undergoing chemoradiation for cancer
treatment. It is believed that colonization of ulcerated mucosa by bacteria, fungi, and virus …

Irinotecan (CPT11), a broad-spectrum cytotoxic anticancer agent, induces a series of toxic
side-effects. The most conspicuous side-effect is gastrointestinal mucositis, including …

Oral mucositis is a common and debilitating side effect induced by stem cell transplantation
that is experienced by cancer patients undergoing chemotherapy or radiation therapy. This …